Over the last couple of weeks, AIM advocates across the country met with over 350 congressional offices to share their stories and advance our policy priorities. With the February 18 deadline looming for Fiscal Year 2022 Appropriations, our advocates asked for increased funding in FY22 for Alzheimer’s and dementia research so we can stay on the path to discovering scientific breakthroughs for this devastating disease. Advocates also requested full funding for the bipartisan Building Our Largest Dementia (BOLD) Infrastructure for Alzheimer’s Act, which directs the Centers for Disease Control and Prevention (CDC) to strengthen the public health infrastructure across the country by implementing effective Alzheimer’s interventions focused on public health issues such as increasing early detection and diagnosis, reducing risk, and preventing avoidable hospitalizations. Lastly, following the proposed national coverage decision on coverage of treatments targeting amyloid for Alzheimer’s released by the Centers for Medicare & Medicaid Services (CMS) on January 11, advocates prioritized discussing this   draft decision and how it essentially blocks coverage of an entire class of potential future treatments.